仲凯励, 苏航, 肖秀斌, 刘静, 鲁云, 陈喜林, 达永, 路春蕾, 张伟京. 剂量调整的EPOCH方案治疗初治血管免疫母T细胞淋巴瘤的前瞻性研究[J]. 中国肿瘤临床, 2014, 41(19): 1229-1233. DOI: 10.3969/j.issn.1000-8179.20141496
引用本文: 仲凯励, 苏航, 肖秀斌, 刘静, 鲁云, 陈喜林, 达永, 路春蕾, 张伟京. 剂量调整的EPOCH方案治疗初治血管免疫母T细胞淋巴瘤的前瞻性研究[J]. 中国肿瘤临床, 2014, 41(19): 1229-1233. DOI: 10.3969/j.issn.1000-8179.20141496
shu
ZHONG Kaili, SU Hang, XIAO Xiubin, LIU Jing, LU Yun, CHEN Xilin, DA Yong, LU Chunlei, ZHANG Weijing. Perspective research of preliminarily diagnosed angioimmunoblastic T-cell lymphoma with dose-adjusted EPOCH regimen[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(19): 1229-1233. DOI: 10.3969/j.issn.1000-8179.20141496
Citation: ZHONG Kaili, SU Hang, XIAO Xiubin, LIU Jing, LU Yun, CHEN Xilin, DA Yong, LU Chunlei, ZHANG Weijing. Perspective research of preliminarily diagnosed angioimmunoblastic T-cell lymphoma with dose-adjusted EPOCH regimen[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(19): 1229-1233. DOI: 10.3969/j.issn.1000-8179.20141496
shu

剂量调整的EPOCH方案治疗初治血管免疫母T细胞淋巴瘤的前瞻性研究

Perspective research of preliminarily diagnosed angioimmunoblastic T-cell lymphoma with dose-adjusted EPOCH regimen

    摘要
  • 摘要:
      目的  前瞻性研究剂量调整的EPOCH方案对初治血管免疫母T细胞淋巴瘤（AITL）患者的疗效及不良反应。
      方法  选择2008年9月至2012年9月中国军事医学科学院附属307医院确诊的初治AITL患者9例。全组患者均接受剂量调整的EPOCH方案一线化疗。
      结果  全组患者发病中位年龄54岁，男:女为2:1，88.9%为Ann-Arbor stage Ⅲ~Ⅳ期，77.8%合并B症状。初诊时伴有贫血的患者占66.7%，LDH或β2微球蛋白升高占55.6%。EPOCH方案近期疗效CR率22.2%，总反应率66.7%。中位随访20个月，4年PFS和OS分别为11.1%和33.3%，中位生存时间19个月。EPOCH方案化疗主要不良反应为血液学毒性，3~4度粒细胞减少和血小板减少分别为77.8%和33.3%，44.4%的患者出现粒细胞缺乏伴发热。
      结论  剂量调整的EPOCH方案一线治疗AITL患者较传统CHOP方案未见明显生存获益。主要不良反应为血液学毒性，并可以耐受。

     

    Abstract:
      Objective  The effect and side effect of the dose-adjusted EPOCH regimen were evaluated perspectively for the preliminarily diagnosed angioimmunoblastic T-cell lymphoma.
      Methods   Nine cases of untreated angioimmunoblastic T-cell lymphoma were diagnosed and enrolled in our department from September 2008 to September 2012. All patients received dose-adjusted EPOCH regimen as first-line chemotherapy.
      Results   The median age of 9 patients was 54 years. The male-to-female ratio was 2 : 1. About 88.9% of all patients were at Ann Arbor stage Ⅲ/Ⅳ, and 77.8% presented with B symptoms. Anemia was found in 66.7% of 9 patients, and lactate dehydrogenase elevated in 55.6% of patients. After an average of 4.7 cycles of chemotherapy of dose-adjusted EPOCH regimen, the complete remission rate was 22.2%, and the total response rate was 66.7%. With a median follow-up of 20 months, the 4-year progression-free survival rate was 11.1%, and the overall survival rate was 33.3%. The median survival time was 19 months. The most common adverse events of EPOCH chemotherapy were hematologic toxicity. Grades 3-4 neutropenia and thrombocytopenia were reported in 77.8% and 33.3% of patients. Febrile neutropenia was observed in 44.4% of patients. Non-treatment-related mortality was also noted.
      Conclusion   The results of our research showed no clear benefit of treating preliminarily diagnosed angioimmunoblastic T-cell lymphoma with dose-adjusted EPOCH regimen. The main adverse events were hematologic toxicity and could be tolerated.

     

    • HTML全文
    • 参考文献(13)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回